RARG and metabolic dysfunction-associated steatotic liver disease: In contrast to the effects of RARβ2 selective agonists on liver steatosis in HFD-induced NAFLD models [89,90,94], the RARα agonist Am 80 exacerbates [95] and the RARγ agonist CD1530 [94] has no major effect on liver steatosis in these models, respectively.